(Q43206243)

English

A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique

scientific article published on 25 December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

Alistair J P Brown

5

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Christophe d'Enfert

9

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Anna Vecchiarelli

12

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

10

object named as

Rino Rappuoli

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Francesco Bistoni

6

object named as

Francesco Bistoni

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Antonio Cassone

11

object named as

Antonio Cassone

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

author name string

Donatella Pietrella

1

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Anna Rachini

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Antonella Torosantucci

3

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Paola Chiani

4

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Paolo Costantino

7

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Paolo Mosci

8

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

language of work or name

0 references

publication date

25 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

1717-1725

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Epidemiology of invasive fungal infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Defining invasive fungal infections in neutropenic or stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Immunopathogenesis of recurrent vulvovaginal candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Pathogenesis and treatment of recurrent vulvovaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Pathogenesis of Recurrent Vulvovaginal Candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Management of patients with recurrent vulvovaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

The protective immune response against vaginal candidiasis: lessons learned from clinical studies and animal models

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Immunity in vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Relation between Recurrent Vulvovaginal Candidiasis, Vaginal Concentrations of Mannose-Binding Lectin, and a Mannose-Binding Lectin Gene Polymorphism in Latvian Women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

History and update on host defense against vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

A novel glyco-conjugate vaccine against fungal pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Utility of the oestrogen-dependent vaginal candidosis murine model in evaluating the efficacy of various therapies against vaginal Candida albicans infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

A multifunctional, synthetic Gaussia princeps luciferase reporter for live imaging of Candida albicans infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

The GPI-modified proteins Pga59 and Pga62 of Candida albicans are required for cell wall integrity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Growth inhibition of Candida albicans by vaginal cells from naïve mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Candida-specific antibodies during experimental vaginal candidiasis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Candida albicans double-stranded DNA can participate in the host defense against disseminated candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Candida albicans ALS3 and insights into the nature of the ALS gene family

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Filamentous growth and elevated vaginopathic potential of a nongerminative variant of Candida albicans expressing low virulence in systemic infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

based on heuristic

inferred from DOI database lookup

MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.12.021

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43206243&oldid=1983828233"